Julio Rosenstock

Julio Rosenstock

UNVERIFIED PROFILE

Are you Julio Rosenstock?   Register this Author

Register author
Julio Rosenstock

Julio Rosenstock

Publications by authors named "Julio Rosenstock"

Are you Julio Rosenstock?   Register this Author

100Publications

2616Reads

23Profile Views

Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.

Diabetes Obes Metab 2019 Sep 24;21(9):2152-2162. Epub 2019 Jun 24.

Cardio-Metabolic Institute, Villingen-Schwenningen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dom.13795DOI Listing
September 2019

Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.

Diabetes Care 2019 Sep 8;42(9):1716-1723. Epub 2019 Jun 8.

Boehringer Ingelheim (Canada) Ltd./Ltée, Burlington, Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/dc19-0548DOI Listing
September 2019

A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses.

Clin Pharmacol Ther 2019 May 13;105(5):1213-1223. Epub 2019 Jan 13.

Tulane University Health Sciences Center, New Orleans, Louisiana, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.1307DOI Listing
May 2019

FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.

Diabetes Obes Metab 2019 05 12;21(5):1073-1078. Epub 2019 Mar 12.

Clinical Development, Therapeutic Area Cardiometabolism, Boehringer Ingelheim, Ingelheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dom.13645DOI Listing
May 2019

Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.

Diabetes Obes Metab 2018 12 7;20(12):2768-2777. Epub 2018 Aug 7.

Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/dom.13457
Publisher Site
http://dx.doi.org/10.1111/dom.13457DOI Listing
December 2018

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.

Diabetes Care 2018 12 4;41(12):2560-2569. Epub 2018 Oct 4.

Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, and Division of Endocrinology and Metabolism, University of Toronto, Toronto, Canada

View Article

Download full-text PDF

Source
http://care.diabetesjournals.org/lookup/doi/10.2337/dc18-174
Publisher Site
http://dx.doi.org/10.2337/dc18-1749DOI Listing
December 2018

Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin.

Diabetes Obes Metab 2018 03 20;20(3):638-645. Epub 2017 Nov 20.

Intarcia Therapeutics, Inc., Boston, Massachusetts and Hayward, Hayward, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dom.13133DOI Listing
March 2018

DPP-4 Inhibitor-Related Pancreatitis: Rare but Real!

Diabetes Care 2017 02;40(2):161-163

Dallas Diabetes Research Center, Dallas, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/dci16-0035DOI Listing
February 2017

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

N Engl J Med 2016 11 15;375(19):1834-1844. Epub 2016 Sep 15.

From the Research Medical Center, Kansas City, MO (S.P.M.); School of Medicine, Swansea University, Swansea, United Kingdom (S.C.B.); Department of Medicine and Aging Science and Center of Excellence on Aging and Translational Medicine, G. d'Annunzio University, Chieti-Pescara, Italy (A.C.); CPClin Research Center/Hospital Israelita Albert Einstein, São Paulo (F.G.E.); Hospital Universitario Quirón Salud Madrid, Facultad de Ciencias de la Salud, Universidad Europea de Madrid, Madrid (E.J.); Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, Toronto (L.A.L.), and the University of Manitoba, Winnipeg (V.W.) - both in Canada; University of Texas Southwestern Medical Center (I.L.) and Dallas Diabetes Research Center at Medical City (J.R.) - both in Dallas; University of Freiburg Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany (J.S.); Physicians East, Greenville, NC (M.L.W.); and Novo Nordisk, Søborg (O.H., A.G.H., J.P.), and the Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup (T.V.) - both in Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1607141DOI Listing
November 2016

Therapy: Gastrointestinal safety of incretin therapies: are we there yet?

Nat Rev Gastroenterol Hepatol 2016 11 21;13(11):630-632. Epub 2016 Sep 21.

Dallas Diabetes Research Center at Medical City, 7777 Forest Lane, Suite C-685, Dallas, Texas 75230, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrgastro.2016.149DOI Listing
November 2016

Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes.

Diabetes Care 2016 Oct 4;39(10):1718-28. Epub 2016 Aug 4.

Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/dc16-0522DOI Listing
October 2016

Response to Comment on Rosenstock and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care 2015;38:1638-1642.

Diabetes Care 2016 08;39(8):e139-40

Institute of Clinical Physiology, Consiglio Nazionale delle Ricerche, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/dci16-0005DOI Listing
August 2016

Getting to the "Heart" of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory".

Diabetes Care 2016 05;39(5):664-7

Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Portland, OR.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/dc16-0405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013718PMC
May 2016

Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents.

Diabetes Care 2015 Dec 7;38(12):2274-81. Epub 2015 Aug 7.

Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/dc15-0629DOI Listing
December 2015

Insulin's Role in Diabetes Management: After 90 Years, Still Considered the Essential "Black Dress".

Diabetes Care 2015 Dec;38(12):2200-3

Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, OR.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/dci15-0023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657614PMC
December 2015

Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.

Diabetes Care 2015 Sep;38(9):1638-42

Institute of Clinical Physiology, Consiglio Nazionale delle Ricerche, Pisa, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/dc15-1380DOI Listing
September 2015

Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges.

Curr Cardiol Rep 2015 Jul;17(7):607

Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11886-015-0607-7DOI Listing
July 2015

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.

Diabetes Care 2014 Aug 4;37(8):2317-25. Epub 2014 Jun 4.

Keenan Research Center, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and Division of Endocrinology and Metabolism, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2337/dc14-0001DOI Listing
August 2014